Literature DB >> 27131295

A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib.

Stefano Frega1, PierFranco Conte1, Matteo Fassan2, Valentina Polo3, Giulia Pasello4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27131295     DOI： 10.1016/j.jtho.2016.01.023

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  8 in total

1.  TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study.

Authors:  Elisna Syahruddin; Jamal Zaini; Ruth Sembiring; Romi Baginta; Muhammad Rizqy Fadhillah; Dimas Ramadhian Noor
Journal:  Asian Pac J Cancer Prev       Date:  2022-01-01

2.  Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.

Authors:  Stefano Frega; Martina Lorenzi; Matteo Fassan; Stefano Indraccolo; Fiorella Calabrese; Adolfo Favaretto; Laura Bonanno; Valentina Polo; Giulia Zago; Francesca Lunardi; Ilaria Attili; Alberto Pavan; Massimo Rugge; Valentina Guarneri; PierFranco Conte; Giulia Pasello
Journal:  Oncotarget       Date:  2017-05-16

3.  The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients.

Authors:  Liming Cao; Long Long; Min Li; Huaping Yang; Pengbo Deng; Xinru Mao; Jianxing Xiang; Bing Li; Tengfei Zhang; Chengping Hu
Journal:  Onco Targets Ther       Date:  2018-05-08       Impact factor: 4.147

4.  The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review.

Authors:  Bao-Dong Qin; Xiao-Dong Jiao; Ling-Yan Yuan; Ke Liu; Zhan Wang; Wen-Xing Qin; Yuan-Sheng Zang
Journal:  Onco Targets Ther       Date:  2018-08-10       Impact factor: 4.147

5.  First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.

Authors:  Xiangyang Yu; Xuewen Zhang; Zichen Zhang; Yongbin Lin; Yingsheng Wen; Yongqiang Chen; Weidong Wang; Lanjun Zhang
Journal:  Cancer Commun (Lond)       Date:  2018-07-28

6.  Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment : integrated computational analysis and in vitro study.

Authors:  Adam Hermawan; Febri Wulandari; Naufa Hanif; Rohmad Yudi Utomo; Riris Istighfari Jenie; Muthi Ikawati; Ahmad Syauqy Tafrihani
Journal:  Sci Rep       Date:  2022-08-17       Impact factor: 4.996

7.  Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report.

Authors:  Bin Zhou; Yanan Wang; Haijiang Liao; Ben Li
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

8.  Efficacy of afatinib for pulmonary adenocarcinoma with leptomeningeal metastases harboring an epidermal growth factor receptor complex mutation (exon 19del+K754E): A case report.

Authors:  Chunhua Ma; Mei Liu; Ning Mu; Jinduo Li; Lin Li; Rong Jiang
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.